Investigation of the Structure of COVID-19 and its Pathogenesis Pathway in the Host: A Review Study

Document Type : Review Article

Author

Undergraduate Student, Department of Biotechnology, Faculty of Biological Sciences, Al-Zahra University, Tehran, Iran

Abstract

Introduction: Coronaviruses have four genera, including alpha, beta, gamma, and delta. The novel coronavirus, coronavirus disease 2019 (COVID-19), is a beta coronavirus type. This is not the first virus that involved the world and viruses have caused serious epidemics and pandemics throughout history. This review study investigated the structure of the COVID-19 virus, host receptors, function of the renin-angiotensin-aldosterone system in the human body, immune system response against the virus, and treatment methods.
Materials and Methods: The present narrative review study used the articles indexed in the international databases, namely Google Scholar, PubMed, ScienceDirect, and PLOS One, and domestic databases, including SID and Magiran, up to 2020. After reviewing the abstracts of 160 articles, similar and unrelated items were discarded. Finally, 52 papers were reviewed in this study.
Results: The obtained results showed that the high tendency of the COVID-19 virus for binding to angiotensin-converting enzyme 2 (ACE2) increased the risk of disease and its transmission. In addition, decreased ACE2 reduced the risk of viral infection; nevertheless, its presence also protected lung cells from damage caused by the virus through the production of angiotensin I-VII.
Conclusion: The formation of bilayer vesicles by coronaviruses prevents the expression of ribonucleic acid (RNA)-recognizing receptors in the host. Because the human body fights viral RNA after its detection and the COVID-19 virus is a packet-type virus, the destruction of the virus pack may be a solution for its eradication. However, for the treatment of the disease caused by the COVID-19 virus, it is necessary to have a thorough perception of the structure and function of the virus in order to find an effective method.

Keywords

References

  1. Kennedy M, Greenacre CB. General concepts of virology. Vet Clin North Am Exot Anim Pract. 2005; 8(1):1-6.
  2. Ganji A, Mosayebi G, Khaki M, Ghazavi A. A review on immunopathogenesis, molcular biology and clinical aspects of the 2019 novel coronavirus (COVID-19). J Arak Univ Med Sci. 2020; 23(1):8-21. [in Persian]
  3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Si HR, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-3.
  4. Macky IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015; 12:222.
  5. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4):418-23.
  6. Farnoosh G, Alishiri G, Hosseini Zijoud SR, Dorostkar R, Jalali Farahani A. Understanding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19) based on available evidence - a narrative review. J Mil Med. 2020; 22(1):1-11. [in Persian]
  7. He J, Tao H, Yan Y, Huang SY, Xiao Y. Molecular mechanism of evolution and human infection with SARS-CoV-2. Viruses. 2020; 12(4):428.
  8. Segar J, Katler Q, McQueen DB, Kotlyar A, Glenn T, Knight Z, et al. Prior and novel coronaviruses, COVID-19, and human reproduction: what is known? J Fertil Steril. 2020; 113(6):1140-9.
  9. Watanable Y, Allen JD, Weapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020; 369(6501):330-3.
  10. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-33.
  11. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015; 1282:1-23.
  12. Wu J, Yuan X, Wang B, Gu R, Li W, Xiang X, et al. Severe acute respiratory syndrome coronavirus 2: from gene structure to pathogenic mechanisms and potential therapy. J Front Microbiol. 2020; 11:1576.
  13. Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19). Singapore: Springer; 2020.
    P. 23-31.
  14. Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020; 526(1):165-9.
  15. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2):631-7.
  16. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87(5):E1-9.
  17. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020;10:587269.
  18. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. 2020; 26:1-13.
  19. Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020; 75(11):2829-45.
  20. Vankadari N, Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interactions. Emerg Microbes Infect. 2020; 9(1):601-4.
  21. Pratt RE, Flynn JA, Hobart PM, Paul M, Dzau VJ. Different secretory pathways of renin from mouse cells transfected with the human renin gene. J Bio Chem. 1998; 263(7):3137-41.
  22. Ziai SA, Mahmoudian M, Keshavarz B, Poorhoseini L, Dastpak A, Ebrahimi A, et al. Study of angiotensin converting enzyme (ACE) inhibitory effects of main Papaver spp. alkaloids. J Med Plants. 2004; 1(9):23-34. [in Persian]
  23. Reid IA. The renin-angiotensin system: physiology, pathophysiology, and pharmacology. Adv Physiol Educ. 1998; 275(6):S236-45.
  24. Reece JB, Urry LA, Cain ML, Wasserman SA, Minorsky PV, Jackson RB. Campbell biology. Boston: Pearson; 2014. P. 1241.
  25. Unger T, Steckelings UM, dos Santos RA. The protective arm of the renin angiotensin system (RAS): functional aspects and therapeutic implications. Massachusetts: Academic Press; 2015. P. 185-9.
  26. Mahmoud IS, Jarrar YB, Alshaer W, Islami S. SARS-CoV-2 entry in host cells – multiple targets for treatment and prevention. Biochimie. 2020; 175:93-8.
  27. Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock. 2016; 46(3):239-48.
  28. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008; 93(5):543-8.
  29. Jannesar M, Seyedi SM. Phylogenetic study and genetic diversity of COVID-19 virus generator. Iran J Culture Health Promot. 2020; 4(1):31-8. [in Persian]  
  30. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky A. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4):586-90.
  31. Liu YC, Kuo RL, Shih SR. COVID-19: the first documented coronavirus pandemic in history. Biomed J. 2020; 43(4):328-33.
  32. Farzanehpour M, Karimi MR, Rezayat P, Bolandian M, Nodoushan MM, Ghaleh HE. A review on the mechanisms involved in the immunopathogenesis of SARS-CoV-2. J Mil Med. 2020; 22(2):147-60. [in Persian]
  33. Mahnam K, Payab N. Proactive cytokines and their containment methods. J Biosaf. 2016; 9(2):74-87. [in Persian]
  34. Golshani Nasab M, Saghazadeh A, Rezaei N. SARS-CoV-2–A tough opponent for the immune system, archives of medical research. Arch Med Res. 2020; 51(6):589-92.
  35. Reece JB, Urry LA, Cain ML, Wasserman SA, Minorsky PV, Jackson RB. Campbell biology. 9th ed. Boston: Pearson; 2014. P. 1175-88.
  36. Tavakoli A, Vahdat K, Keshavarz M. Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. Iran South Med J. 2020; 22(6):432-50. [in Persian]
  37. Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med. 2020; In Press.
  38. Ganjloo J, Ghazanfari M. Report of a rare case of unprescribed long-term use of dexamethasone injection for 20 years. J Sabzevar Univ Med Sci. 2009; 16(4):240-3. [in Persian]
  39. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594):381-5.
  40. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396):
    eaal3653.
  41. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018; 9(2):e00221.
  42. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017; 7:43395.
  43. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020; 6(3):315-31.
  44. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009; 81(2):132-40.
  45. Kearney J. Chloroquine as a potential treatment and prevention measure for the 2019 novel coronavirus: a review. Preprints. 2020; 17:1-24.
  46. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949.
  47. Sheykhhasan M, Manoochehri H, Saidijam M. New therapeutic strategies in treating the new Coronavirus 2019: review article. Tehran Univ Med J. 2020; 78(5):261-73. [in Persian]
  48. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: the current state of play. Paediatr Respir Rev . 2020; 35:43-9.
  49. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255):887-97.
  50. Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020; 8(11):e85-6.
  51. Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020; 395(10239):1751-2.
  52. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020; 383(20):1920-31.
Navid No
Volume 24, Issue 77
June 2021
Pages 108-120

Files

Share

How to cite

Statistics